PROCESSA PHARMACEUTICALS INC (PCSA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.84-5.15%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PCSA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
[TABLE] Page 3 of 6 [/TABLE] What To Expect From Us Our focus is now on executing our broader I&I strategy: advancing the planned Phase 2 proof-of-concept programs for VT-7208, progressing our FcRn p…
Stated in 1 of 1 supplied quarters. Management reported: “The FDA has cleared the IND application for our planned Phase 2 clinical trial of VT-7208 in CSU, allowing us to move forward with the study in this large patient population.” “Processa expects to initiate Phase 2 studies in food allergy and CSU in the second half of 2026, and in RMS in the first half of 2027, with multiple anticipated clinical milestones across the pipeline expected over the next 12–24 months.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“[TABLE] Page 3 of 6 [/TABLE] What To Expect From Us Our focus is now on executing our broader I&I strategy: advancing the planned Phase 2 proof-of-concept programs for VT-7208, progressing our FcRn p…”
A Clear Execution Roadmap The July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, including support for the previous…
Stated in 1 of 1 supplied quarters. Management reported: “A Clear Execution Roadmap The July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, including support for the previously disclosed Phase 2 proof-of-concept development plan across the three indications we are initially pursuing: food allergy, CSU and relapsing MS. Beyond VT-7208, we are building a broader pipeline of differentiated therapies for immune-mediated diseases.” “The company’s cash and cash equivalents at closing, including gross proceeds expected from the concurrent private placement financing, are expected to fund operations into the second half of 2029.”
“A Clear Execution Roadmap The July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, including support for the previous…”
Our second program is a novel, oral macrocyclic peptide-based neonatal Fc receptor, or FcRn, antagonist program being advanced through a research collaboration and exclusive option agreement with Gen…
Stated in 1 of 1 supplied quarters. Management reported: “Our second program is a novel, oral macrocyclic peptide-based neonatal Fc receptor, or FcRn, antagonist program being advanced through a research collaboration and exclusive option agreement with Generian Pharmaceuticals.” “The Vidya transaction gave Processa a lead clinical-stage program, the foundation for a broader I&I pipeline, a defined development strategy and financing expected to support operations for the planned Phase 2 proof-of-concept clinical trials in all three initial indications.”
“Our second program is a novel, oral macrocyclic peptide-based neonatal Fc receptor, or FcRn, antagonist program being advanced through a research collaboration and exclusive option agreement with Gen…”
Advance VT-7208 through multiple Phase 2 proof-of-concept studies in food allergy, CSU, and RMS with key clinical milestones expected in 2027 and 2028.
Raise approximately $200 million through a private placement financing to fund operations and clinical development through key milestones.
Over the trailing year it converted 0.93x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
21 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.